anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: This study aimed to evaluate the morbidity associated with excisional biopsy in patients with spontaneous gastric perforation.
METHODS: A retrospective, single-center, observational study was performed. All consecutive patients with spontaneous gastric perforation who underwent surgical therapy were included. Outcomes were assessed concerning the performance of excisional biopsy.
RESULTS: A total of 135 adult patients were enrolled. Of these, 110 (81.5%) patients underwent excisional biopsy, while 17 (12.6%) did not. The remaining eight (5.9%) patients who underwent gastric resection were excluded from the analysis. Patients undergoing excisional biopsy developed significantly higher rates of postoperative complications (p = 0.007) and experienced more severe complications according to the Clavien-Dindo classification, particularly type III and above (p = 0.017). However, no significant differences were observed regarding in-hospital mortality, reoperation, suture dehiscence, or length of hospital stay.
CONCLUSION: Excisional biopsy for gastric perforation has been shown to be associated with increased morbidity. Surgical closure followed by early endoscopic biopsy may be a superior approach for gastric perforation management to rule out malignancy.
This program consists of an exercise dosage of 180 min/week administered in 3 sessions of 60 minutes. Each session includes 10 minutes of warm-up exercise before the main exercise and 10 minutes of cool-down afterwards.the principal exercise section includes 20 minutes of aerobic exercise and 20 minutes of resistance and strength exercises. The exercise intensity will be regulated according to the heart rate measured by a pulsimeter throughout the exercise. The target intensity level will be individualized according to the heart rate to set the moderate intensity level (HR values between ventilatory thresholds) and high intensity level (HR values from 2nd. ventilatory threshold to the peak threshold).
PROBLEM TO BE SOLVED: To provide an easily producible skin-beautifying agent very useful for beautifying the skin and also preventing/treating various dermatoses. SOLUTION: This skin-beautifying agent is obtained by mixing vinegar with common salt. When the agent is applied to the hands or legs, the relevant skin becomes smooth and dampish. When the agent is applied to rough skin, for example, chapped hands, the symptoms can be cured. Furthermore, the agent has fungicidal effect, not only serving as a prophylaxis for dermatophytosis or the like but also enabling the symptoms to be mitigated or cured when applied to the affected parts associated with dermatophytosis. Besides, the agent has efficacy for dermatoses other than dermatophytosis.
PURPOSE:An ameliorant of enteric function containing an epidermal growth factor,a derivative or salt thereof as an active ingredient. CONSTITUTION:An ameliorant of enteric function obtained by blending an epidermal growth factor (EGF; obtained from living bodies of mammals. e.g. rat or mouse, etc., or from urine or humans or horses, etc., or artificially prepared, a derivative or salt thereof as an active ingredient with other ingredients. Examples of the dosage form include capsule, granule, pill, syrup, injection suppository, etc., and can be orally or parenterally administered. Another drug may be, as necessary, blended. The dose thereof is preferably 1mug-1mg/adult/ day (parenteral administration) expressed in terms of the active ingredient polypeptide. EFFECT:The intestinal tract peristalitic movement is specifically enhanced without causing side effect. The ameliorant has analgesic, anti-inflammatory action and wound curing promotion action, etc., together with low toxicity.
The aim of the current study is to develop and pilot test an anxiety-sensitivity based intervention for co-occurring SUDs and anxiety. In the proposed study, the investigators will develop, refine, and pilot-test an innovative cognitive-behavioral therapy (CBT) for patients who suffer from substance use disorders as well as anxiety. The goal of the research group in the proposed study is to design a protocol that can be testable on a larger sample within an externally-funded, randomized controlled trial. The investigators plan to submit a proposal for this larger grant to the National Institute on Drug Abuse, as outlined in our external funding statement.

Research questions include determining whether a broadly-applicable anxiety sensitivity based intervention can significantly decrease both substance misuse and anxiety. Secondary aims include examining the impact of this intervention on general functioning and depressive/anxious symptoms. In this translational research project, strategies that have been demonstrated to impact the psychological mechanisms thought to underlie both illnesses will be tested in a "real world" clinical setting.
The invention relates to a silica-coated fluorescent magnetic nanoparticle modified by amino or ester dendrimer. A superparamagetism Fe3O4 inner core is prepared by using a coprecipitation method; Fe3O4 encapsulated by silicon dioxide (Fe3O4 and SiO2) is formed by alkaline hydrolyzation of tetraethoxysilane (TEOS); and a fluorescent dye (fluorescein isothiocyanate FITC) is encapsulated in the silicon dioxide layer in a covalent way so as to facilitate tracing a carrier or to be taken as a model medicament. The carrier can be used for fluorescent tracing; and the external surface of the carrieris coated with polyamide-amine (PAMAM) dendrimer, so that the carrier has a great amount of functional groups used for modifying and used for connecting antibodies easier to target a blood brain barrier, and has the potential of becoming a targeted medicament carrier. Research results show that the two materials are injected through arteria carotis communis and can pass through the blood brain barrier. The ester silica-coated fluorescent magnetic nanoparticle is easier to pass through the blood brain barrier than the amino silica-coated fluorescent magnetic nanoparticle. In addition, the carrier can also be used for marking cells.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to condensed derivatives of 1,2,4-thiadiazine comprising thiophene and 1,2,4-thiadiazole rings in the system. Invention describes also pharmaceutical composition and for preparing medicine based on these compounds. Compounds show capacity to effect on K+ÊÈ-regulated potassium channels that is useful in treatment of endocrine system, in part, they can be used for reduction of hyperinsulinemia and, therefore, for prophylaxis of diabetes mellitus. EFFECT: improved preparing method, valuable medicinal properties of medicine. 8 cl, 30 ex
In phase I, subjects will be randomized into either the Vivomixx probiotics or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotics (4 sachets/ day or 1800 billion bacteria/day) or placebo (4 placebo sachets/day) for the first 60 days.
BACKGROUND: In Germany, there is no data available on the frequency of inpatient rehabilitation (IR) after elective endovascular (EVAR) and open (OAR) abdominal aortic aneurysm (AAA) repair.
OBJECTIVE: To report for the first time on the outcome of patients 65 years and older and thus of retirement age with and without IR after AAA repair in a retrospective analysis of routine data from all eleven regional companies of the AOK health insurance fund (AOK-Gesundheit).
METHODS: Anonymized data of 16,358 patients 65 years and older with intact abdominal aortic aneurysm treated with EVAR (n = 12,960) or OAR (n = 3,398) between 01/01/2010 and 12/31/2016 were analyzed. Patients with postoperative IR (n = 1,531) were compared to those without postoperative IR (n = 14,827) with respect to general patient characteristics, comorbidities, perioperative and postoperative outcomes, and survival. The average follow-up of patients with postoperative and without postoperative IR was 49.9 months and 51.8 months, respectively.
RESULTS: 5.4% of EVAR patients, but 24.6% of OAR patients were referred to IR (p < 0.001). Patients with IR were sicker than those without IR. Parameters significantly influencing the use of IR included OAR vs EVAR (Odds Ratio [OR] 6.03), condition after cerebral infarction (OR 1.53), and women vs men (OR 1.49). Perioperative influencing parameters were cerebral infarction (OR 2.40), blood transfusions (OR 2.21) and complex critical care (OR 2.15). After nine years, the Kaplan-Meier estimated survival was 41.9% for patients with vs 43.4% for those without IR in the EVAR group (p = 0.178). For OAR, it was 50.2% for patients with IR vs 49.8% for patients without IR (p = 0.006). In multivariate regression analysis, postoperative IR had a significant effect on long-term survival in OAR but not in EVAR patients.
CONCLUSION: There are no generally binding guidelines for the indication of IR after AAA repair. It should therefore be a requirement for the future that the fitness of each patient with elective AAA repair be determined with a score before and after the procedure in order to make indications for AHB more comparable. The score should be documented in the hospital discharge letter.
Cachexia is characterized by severe weight loss and skeletal muscle depletion, and is a threat to cancer patients by worsening their prognosis. International guidelines set indications for the screening and diagnosis of cancer cachexia and suggest interventions (nutritional support, physical exercise, and pharmacological treatments). Nevertheless, real-life experience not always aligns with such indications. We aimed to review the current state of the field and the main advancements, with a focus on real-life clinical practice from the perspectives of oncologists, nutrition professionals, and radiologists. Pragmatic solutions are proposed to improve the current management of the disease, emphasizing the importance of increasing awareness of clinical nutrition's benefits, fostering multidisciplinary collaboration, promoting early identification of at-risk patients, and leveraging available resources. Given the distinct needs of patients who are receiving oncologic anti-cancer treatments and those in the follow-up phase, the use of tailored approaches is encouraged. The pivotal role of healthcare professionals in managing patients in active treatment is highlighted, while patient and caregiver empowerment should be strengthened in the follow-up phase. Telemedicine and web-based applications represent valuable tools for continuous monitoring of patients, facilitating timely and personalized intervention through effective communication between patients and healthcare providers. These actions can potentially improve the outcomes, well-being, and survival of cancer patients with cachexia.
Domestic dogs have great potential to expand our understanding of the determinants of aging. To understand the aging pattern of domestic dogs and evaluate whether they can be used as an aging model, we performed RNA sequencing on white blood cells from domestic dogs aged 1-9 years and treated aged dogs with classical antiaging approaches. We obtained 30 RNA sequencing libraries and identified 61 age-associated genes with dynamic changes, the majority of which were related to metabolism and immune function, which may be predominant biomarkers for aging in dogs. We next treated aged dogs with canine mesenchymal stem cells (cMSCs), nicotinamide mononucleotide, and rapamycin to determine whether and how they responded to the antiaging interventions. The results showed that these treatments can significantly reduce the level of inflammatory factors (IL-6 and TNF-α). MSCs effectively improved the heart functions of aged dogs. Three key potential age-related genes (PYCR1, CCRL2, and TOX) were reversed by MSC treatment, two of which (CCRL2 and TOX) are implicated in immunity. Overall, we profiled the transcriptomic pattern of domestic dogs and revealed that they may be a good model of aging, especially in anti-inflammatory investigations.
PROBLEM TO BE SOLVED: To produce high purity tetracalcium phosphate with a comparatively simple process by heating an aqueous suspension of equimolar powdery CaHPO4 .2H2 O and fine powder CaCO3 to a specified temp., maintaining the suspension at this temp. to form a reaction product and calcining the reaction product. SOLUTION: In this production, powder CaHPO4 .2H2 O and fine powder CaCO3 are mixed together in a molar ratio of 1:1 to form an aqueous suspension and thereafter, the resulting suspension is heated to a temp. above 70 deg.C and maintained at this temp. to allow it to react to form a reaction product and then, the reaction product is calcined to produce the objective tetracalcium phosphate. As the CaCO3 used, it is required to use particles as fine as possible. When the particle size of CaCO3 is large, the reaction proceeds insufficiently at a temp. above 70 deg.C and unreacted powdery CaCO3 , remains in the reaction product. From this viewpoint, CaCO3 fine particles having a <=5μm average particle size are preferred as the fine powder CaCO3 .
The efficacy and safety of tadalafil for once daily use in the treatment of erectile dysfunction has been evaluated in 2 clinical trials of 12 weeks duration and 1 clinical trial of 24 weeks duration, involving a total of 853 patients. Tadalafil, when taken once daily, was shown to be effective in improving erectile function in men with erectile dysfunction (ED).

Tadalafil was studied in the general ED population in 2 randomized, multicenter, double-blinded, placebo-controlled, parallel-arm design, primary efficacy and safety studies of 12- and 24-weeks duration, respectively. One of these studies was conducted in the United States and one was conducted in centers outside the US. An additional efficacy and safety study was performed in ED patients with diabetes mellitus. Tadalafil was taken once daily at doses ranging from 2.5 to 10 mg. Food and alcohol intake were not restricted. Timing of sexual activity was not restricted relative to when patients took tadalafil.

Results in General ED Population 

The primary US efficacy and safety trial included a total of 287 patients, with a mean age of 59 years (range 25 to 82 years). The population was 86% White, 6% Black, 6% Hispanic, and 2% of other ethnicities, and included patients with ED of various severities, etiologies (organic, psychogenic, mixed), and with multiple co-morbid conditions, including diabetes mellitus, hypertension, and other cardiovascular disease. Most (>96%) patients reported ED of at least 1 year duration.

The primary efficacy and safety study conducted outside the US included 268 patients, with a mean age of 56 years (range 21 to 78 years). The population was 86% White, 3% Black, 0.4% Hispanic, and 10% of other ethnicities, and included patients with ED of various severities, etiologies (organic, psychogenic, mixed), and with multiple co-morbid conditions, including diabetes mellitus, hypertension, and other cardiovascular disease. Ninety-three percent of patients reported ED of at least 1 year duration. 

In each of these trials, conducted without regard to the timing of dose and sexual intercourse, tadalafil demonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary (see Table 17). When taken as directed, tadalafil was effective at improving erectile function. 

In the 6 month double-blind study, the treatment effect of tadalafil did not diminish over time. 

Efficacy Results in ED Patients with Diabetes Mellitus 

Tadalafil for once daily use was shown to be effective in treating ED in patients with diabetes mellitus. Patients with diabetes were included in both studies in the general ED population (N=79). A third randomized, multicenter, double-blinded, placebo-controlled, parallel-arm design trial included only ED patients with type 1 or type 2 diabetes (N=298). In this third trial, tadalafil demonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary (see Table 18).
PURPOSE:To control the contraction during polymerization with oxide particles and to improve the characteristic of the title sol after curing by using a reactive monomer having a polymerizable unsaturated bond as >=80% of a dispersion medium to prepare the oxide sol. CONSTITUTION:The reactive monomer having a polymerizable unsaturated bond in the molecule is blown into the hydrosol of an oxide or the organosol using a nonpolymerizable org. solvent as the dispersion medium. Then water or the org. solvent is distilled under reduced pressure to substitute the dispersion medium for the reactive monomer and the oxide sol is prepared. In this case, >=80% of the dispersion medium must be substituted for the reactive monomer. An ethylenic unsaturated bond is preferably used as the polymerizable unsaturated bond and acrylic acid, acrylic ester, or alpha-substituted acrylic ester are preferably used as the reactive monomer.
The silkworm, Bombyx mori, stands out as one of the few economically valuable insects within the realm of model organisms. However, Bombyx mori nucleopolyhedrovirus (BmNPV) poses a significant threat, decreasing the quality and quantity of silkworm cocoons. Over the past few decades, a multitude of researchers has delved into the mechanisms that underlie silkworm resistance to BmNPV, employing diverse methodologies and approaching the problem from various angles. Despite this extensive research, the role of alternative splicing (AS) in the silkworm's response to BmNPV infection has been largely unexplored. This study leveraged both third-generation (Oxford Nanopore Technologies) and second-generation (Illumina) high-throughput sequencing technologies to meticulously identify and analyze AS patterns in the context of BmNPV response, utilizing two distinct silkworm strains-the susceptible strain 306 and the resistant strain NB. Consequently, we identified five crucial genes (Dsclp, LOC692903, LOC101743583, LOC101742498, LOC101743809) that are linked to the response to BmNPV infection through AS and differential expression. Additionally, a thorough comparative analysis was conducted on their diverse transcriptomic expression profiles, including alternative polyadenylation, simple sequence repeats, and transcription factors.
Shiny orthodontic bracket (A) comprising a suitable material which contains a radiant pigment. The following are also claimed: (i) a phosphorescent orthodontic synthetic bracket (B) comprising a polycarbonate bracket material reinforced with ca. 20-40 wt.% glass fibres and contg. ca 10-15 wt.% zinc sulphide as a phosphorescent pigment in combination with copper and (ii) a shiny orthodontic bracket archwire (C) contg. a radiant pigment; (iii) a shiny orthodontic appliance (D) used to move teeth in order to correct bite and tooth position, comprising a material contg. a radiant pigment.
The mechanisms of action of vincristine sulfate remain under investigation. The mechanism of action of vincristine sulfate has been related to the inhibition of microtubule formation in mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage.

Central nervous system leukemia has been reported in patients undergoing otherwise successful therapy with vincristine sulfate. This suggests that vincristine does not penetrate well into the cerebrospinal fluid.

Pharmacokinetic studies in patients with cancer have shown a triphasic serum decay pattern following rapid intravenous injection. The initial, middle and terminal half–lives are 5 minutes, 2.3 hours, and 85 hours respectively; however, the range of the terminal half–life in humans is from 19 to 155 hours. The liver is the major excretory organ in humans and animals. The metabolism of vinca alkaloids has been shown to be mediated by hepatic cytochrome P450 isoenzymes in the CYP 3A subfamily. This metabolic pathway may be impaired in patients with hepatic dysfunction or who are taking concomitant potent inhibitors of these isoenzymes (see PRECAUTIONS). About 80% of an injected dose of vincristine sulfate appears in the feces and 10% to 20% can be found in the urine. Within 15 to 30 minutes after injection, over 90% of the drug is distributed from the blood into tissue, where it remains tightly, but not irreversibly, bound.

Current principles of cancer chemotherapy involve the simultaneous use of several agents. Generally, each agent used has a unique toxicity and mechanism of action so that therapeutic enhancement occurs without additive toxicity. It is rarely possible to achieve equally good results with single–agent methods of treatment. Thus, vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy). See DOSAGE AND ADMINISTRATION section for possible increased toxicity when used in combination therapy.
Females usually tend to avoid physical activity during pregnancy. Concept of antenatal exercises and its effects on low back pain or antenatal depression is yet not common amongst pregnant females in Pakistan. Low back pain and antenatal depression are common in pregnancy. These can have an impact on both their own health and the health of their unborn child. Understanding the benefits of antenatal exercises will encourage pregnant females to engage in regular physical activity. The results of this study will help physical therapists to implement effective exercise interventions for this population.
A lignin-loaded paclitaxel nanoparticle and a preparation method thereof relate to the technical field of biological medicine, in particular to a lignin-loaded paclitaxel nanoparticle and a preparation method thereof. Aims to solve the problems of high cytotoxicity and over-rapid drug release of the existing lignin drug-encapsulated material. The nanoparticle comprises a lignin-coated material and paclitaxel, wherein the lignin-coated material is prepared from modified lignin. The method comprises the following steps: firstly, modifying lignin; secondly, preparing a lignin carrying material; and thirdly, blending the lignin-loaded material and paclitaxel to prepare the lignin-loaded paclitaxel nanoparticles. The lignin-loaded paclitaxel nanoparticles have biocompatibility and targeting property, and have good anticancer effect, and the lignin-loaded material has the characteristics of low toxic and side effects and targeted slow release. The invention is used for encapsulating the medicine paclitaxel.